The general sense is that Tetraphase will be bought before Phase 3 results come out. Brean's report confirmed prevailing street sentiment. Any thoughts on what a deal might look like? Prrojected sales x2 seems reasonable given what we saw with Merck and Actavis, but when you add in CRE, it seems the value may be higher. Assuming eravacycline has the potential to be a billion dollar drug (particularly given CRE efficacy), that would put us around a $74 buyout. Thoughts on who might be interested? It wasn't mentioned in Brean's report Friday, but perhaps Glaxo or Pfizer would be interested to compete with Merck's acquisition of Cubist.